Q4 2025 Recursion Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Recursion Pharmaceuticals Inc (RXRX) has achieved its first positive proof of concept with FAP, indicating potential for a first-in-class treatment.
- The company has extended its cash runway into early 2028, demonstrating strong financial management and sustainability.
- Recursion Pharmaceuticals Inc (RXRX) has achieved a fifth milestone with Sanofi, reflecting successful partnerships and joint portfolio growth.
- The company has reduced pro forma operating expenses by 35% year over year, showcasing effective cost management.
- Recursion Pharmaceuticals Inc (RXRX) has a diversified portfolio with multiple programs in clinical development, indicating a broad approach to drug discovery.
- The company faces challenges in translating AI-driven insights into tangible clinical outcomes, which remains a critical focus.
- There is a high failure rate in drug discovery and development, with a 90% failure rate acknowledged by the company.
- Recursion Pharmaceuticals Inc (RXRX) is still in the early stages of proving the repeatability and scalability of its platform in clinical settings.
- The company is heavily reliant on partnerships and milestones for financial inflows, which can be unpredictable.
- Despite progress, the company acknowledges that drug discovery and development is inherently probabilistic and challenging.
Good morning, everyone, and thank you so much for joining us.
I want to start by briefly framing where recursion is today in its journey and evolution.
Over the past decade, recursion has built something truly special, a differentiated platform, pioneering the integration of large-scale biological data generation, machine learning, and compute to better understand the complexity of biology.
We have also deliberately strengthened the foundation in chemistry and AI through the acquisitions of Excientia, Valence, and Cyclia, creating a truly powerful foundation.
Today, we're at an important inflection point.
We're harnessing everything that we've built to date.
To do two things. Number 1, translating insights into evidence. Evidence that this platform, the use of AI end to end, can generate medicines that matter.
And we're doing this both across our wholly owned portfolio and through our partnerships with strong momentum across both fronts. I'm excited to share
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
